SOURCE: Neurogenesis, Inc.

November 21, 2013 08:30 ET

NeuroGenesis Dietary Supplements Are Covered by Issued Patents

LEAGUE CITY, TX--(Marketwired - November 21, 2013) - NeuroGenesis, Inc. (PINKSHEETS: NEUN) has been marketing and selling a variety of patented supplements into the large supplement marketplace for over 25 years. The Company's products range from Neu BeCalm'd (beneficial for relief of stress; improves mental focus and concentration; helps establish normal sleep patterns) to NeuRelieve (supplements to replenish neurotransmitters depleted by benzodiazepine), NeuRecover (supplements to replenish neurotransmitters depleted by alcohol), NeuReplenish (supplements to replenish neurotransmitters depleted by use of chemical stimulants) and NeuSlim (provides nutritional support for healthy weight loss and maintenance). With over 30 years of scientific research and clinical studies and use in over 1,700 US hospitals and drug rehab centers.

The Company currently has three "use" patents that relate to the ingredients in NeuroGenesis products. A "use" patent is the exclusive right to use a substance in a specific way. You can find more information on the Company's website at:


After additional intense research, NeuroGenesis, a supplement formulator discovered that the Neu BeCalm'd approach is the most effective means of providing a long lasting solution to chemical balances in the brain. While most types of traditional medicine treat the symptoms, the Neu BeCalm'd product addresses the underlying issues in order to help one achieve a normal life. In addition, the Neu BeCalm'd formulation contains FDA approved nutritional ingredients. Neu BeCalm'd has been reported to be beneficial in reducing the effects of acute as well as chronic stress factors in those who use the product.

Neu BeCalm'd is a safe, all natural alternative to traditional medicine, and is intended for people with PTSD and other similar problems. In addition, Neu BeCalm'd contains formulations of vitamins, minerals and amino acids that are designed to assist the brain in balancing and rebuilding neurotransmitters to achieve and maintain a chemical balance.

Forward-looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which contain words such as "expect," "believe" or "plan," by their nature address matters that are, to different degrees, uncertain. These uncertainties may cause actual future events to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

Contact Information